Related Experiment Video

Updated: Mar 26, 2026

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

22.0K

Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma

Pierre Sujobert1, Catherine Rioufol, Gilles A Salles

  • 1From the *Faculté de Médecine Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon-1; †Laboratoire d'Hématologie Biologique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud; ‡INSERM U1052, Equipe "Clinical and Experimental Models of Lymphomagenesis," Cancer Research Center of Lyon; and §Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon; ‖Université Claude Bernard Lyon-1, EMR 3738, Pierre-Bénite; and ¶Service d'Hématologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.

Cancer Journal (Sudbury, Mass.)
|February 4, 2016
PubMed

Insights

Idelalisib, a targeted therapy, effectively treats B-cell malignancies by inhibiting phosphatidylinositol 3-kinase delta. This drug shows promise in lymphomas and chronic lymphocytic leukemia, despite some adverse events.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Phosphatidylinositol 3-kinase delta (PI3Kδ) is a key target in B-cell malignancies due to its role in tumor cell proliferation and microenvironment.
  • Restricted hematopoietic expression of PI3Kδ makes it an attractive therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy and safety of idelalisib, a PI3Kδ-specific inhibitor, in patients with B-cell lymphomas and chronic lymphocytic leukemia.
  • To determine the therapeutic potential of idelalisib in various B-cell malignancy subtypes.

Main Methods:

  • Clinical trials involving patients with B-cell lymphomas and chronic lymphocytic leukemia.
  • Assessment of antitumor effects, response rates, and duration of response.
  • Monitoring of adverse events, including transaminitis, neutropenia, pneumonitis, and diarrhea.

Main Results:

  • Idelalisib demonstrated potent antitumor effects in indolent and mantle cell lymphomas.
  • A pivotal phase II study in refractory disease showed a 57% response rate, with responses lasting approximately 1 year.
  • Adverse events were observed, necessitating careful patient monitoring.

Conclusions:

  • Idelalisib is an effective treatment for certain B-cell malignancies, including indolent lymphomas and chronic lymphocytic leukemia.
  • Further research into idelalisib combinations is warranted to optimize its role in therapeutic strategies.
  • Idelalisib has received market approval in the US and Europe for specific indications.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K